Identifying aggressive prostate cancer at diagnosis using advanced imaging and biomarker techniques
Official title: Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches
Funded at Washington University · NIH-10884411 · Data updated 2026-11-12
This study is looking to help doctors find dangerous prostate cancer more accurately when patients are first diagnosed by using new imaging techniques and special tests, so they can better decide on the right treatment for those at higher risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $592,860 |
| NIH project number | 5R01CA282022-02 |
| Project ID | NIH-10884411 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer who are at risk of developing lethal forms of the disease.
✕Less likely to help
Patients with benign prostate conditions or those with advanced metastatic prostate cancer may not benefit from this research.
What this research studies
This research aims to improve the identification of lethal prostate cancer at the time of diagnosis by utilizing advanced imaging techniques and biomarker analysis. It focuses on enhancing the sensitivity and specificity of magnetic resonance imaging (MRI) through a novel approach called diffusion basis spectral imaging (DBSI), which can detect critical changes in the prostate microenvironment. Additionally, the study investigates specific extracellular proteoglycomic biomarkers associated with aggressive forms of prostate cancer. By accurately identifying high-risk patients, the research seeks to inform treatment decisions and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses of aggressive prostate cancer, allowing for timely and effective treatment options.
How similar studies have gone: Previous research has shown promise in using advanced imaging techniques and biomarkers for cancer diagnosis, indicating potential success for this novel approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Ippolito, Joseph Edward — Washington University
- Study coordinator: Ippolito, Joseph Edward
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.